TriangleNCT01876511 · OUTCOME
Progression Free Survival (PFS) at 28 Weeks in MSI Positive and Negative Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 28 weeks
What was measured
PFS is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 28 weeks. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
Groups in this outcome
Cohort A: MSI Positive Colorectal Cancer
MK-3475: MK-3475 10 mg/kg every 14 days
Cohort B: MSI Negative Colorectal Cancer
MK-3475: MK-3475 10 mg/kg every 14 days
Cohort C: MSI Positive Non-Colorectal Cancer
MK-3475: MK-3475 10 mg/kg every 14 days
| Group | Source count |
|---|---|
| Cohort A: MSI Positive Colorectal Cancer | 41 |
| Cohort B: MSI Negative Colorectal Cancer | 25 |
| Cohort C: MSI Positive Non-Colorectal Cancer | 47 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cohort A: MSI Positive Colorectal Cancer | 70 | Not reported | 57 | 86 | Not reported |
| Cohort B: MSI Negative Colorectal Cancer | 16 | Not reported | 6 | 41 | Not reported |
| Cohort C: MSI Positive Non-Colorectal Cancer | 64 | Not reported | 51 | 79 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 57
- upper Limit
- 86
- value
- 70
- group Id
- OG001
- lower Limit
- 6
- upper Limit
- 41
- value
- 16
- group Id
- OG002
- lower Limit
- 51
- upper Limit
- 79
- value
- 64
- denoms
- counts
- group Id
- OG000
- value
- 41
- group Id
- OG001
- value
- 25
- group Id
- OG002
- value
- 47
- units
- Participants
- description
- PFS is defined as the percentage of patients with disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria) or death due to any cause at 28 weeks. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =\>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is \>20% increase in sum of diameters of target lesions, Stable Disease (SD) is \<30% decrease or \<20% increase in sum of diameters of target lesions. Estimation based on the Kaplan-Meier curve.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- MK-3475: MK-3475 10 mg/kg every 14 days
- id
- OG000
- title
- Cohort A: MSI Positive Colorectal Cancer
- description
- MK-3475: MK-3475 10 mg/kg every 14 days
- id
- OG001
- title
- Cohort B: MSI Negative Colorectal Cancer
- description
- MK-3475: MK-3475 10 mg/kg every 14 days
- id
- OG002
- title
- Cohort C: MSI Positive Non-Colorectal Cancer
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 28 weeks
- title
- Progression Free Survival (PFS) at 28 Weeks in MSI Positive and Negative Solid Tumor Malignancies Using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Independent clinical review pending · Not medical advice